Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2000 1
2002 1
2003 1
2004 3
2005 4
2006 3
2007 3
2008 9
2009 9
2010 17
2011 22
2012 19
2013 15
2014 14
2015 10
2016 9
2017 6
2018 7
2019 8
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

139 results
Results by year
Filters applied: . Clear all
Page 1
Mechanisms of endocrine resistance in breast cancer.
Osborne CK, Schiff R. Osborne CK, et al. Annu Rev Med. 2011;62:233-47. doi: 10.1146/annurev-med-070909-182917. Annu Rev Med. 2011. PMID: 20887199 Free PMC article. Review.
Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Dobrolecki LE, et al. Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Cancer Metastasis Rev. 2016. PMID: 28025748 Free PMC article. Review.
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. Jeselsohn R, et al. Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30. Nat Rev Clin Oncol. 2015. PMID: 26122181 Free PMC article. Review.
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF. Kessler JD, et al. Science. 2012 Jan 20;335(6066):348-53. doi: 10.1126/science.1212728. Epub 2011 Dec 8. Science. 2012. PMID: 22157079 Free PMC article.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. Fu X, et al. Proc Natl Acad Sci U S A. 2019 Dec 11;116(52):26823-34. doi: 10.1073/pnas.1911584116. Online ahead of print. Proc Natl Acad Sci U S A. 2019. PMID: 31826955 Free PMC article.
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
Sukumaran S, Watanabe N, Bajgain P, Raja K, Mohammed S, Fisher WE, Brenner MK, Leen AM, Vera JF. Sukumaran S, et al. Cancer Discov. 2018 Aug;8(8):972-987. doi: 10.1158/2159-8290.CD-17-1298. Epub 2018 Jun 7. Cancer Discov. 2018. PMID: 29880586 Free PMC article.
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.
Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. Parashar D, et al. Cell Rep. 2019 Dec 24;29(13):4389-4406.e10. doi: 10.1016/j.celrep.2019.11.085. Cell Rep. 2019. PMID: 31875548 Free PMC article.
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF. Nair A, et al. Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26. Nat Med. 2018. PMID: 29578538 Free PMC article.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. Nardone A, et al. Br J Cancer. 2019 Feb;120(3):331-339. doi: 10.1038/s41416-018-0354-9. Epub 2018 Dec 17. Br J Cancer. 2019. PMID: 30555156 Free PMC article.
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R. Sethunath V, et al. Mol Cancer Res. 2019 Nov;17(11):2318-2330. doi: 10.1158/1541-7786.MCR-19-0756. Epub 2019 Aug 16. Mol Cancer Res. 2019. PMID: 31420371 Free PMC article.
139 results
Jump to page
Feedback